Related Experiment Video

Updated: Mar 26, 2026

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

1.7K

Insulin-Like Growth Factor II mRNA-Binding Protein 3 Expression Correlates with Poor Prognosis in Acral Lentiginous

Yi-Shuan Sheen1,2, Yi-Hua Liao1, Ming-Hsien Lin3,4

  • 1Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.

Plos One
|January 23, 2016
PubMed

Insights

Insulin-like growth factor-II mRNA-binding protein 3 (IMP-3) is overexpressed in acral lentiginous melanoma (ALM). Positive IMP-3 expression indicates a poorer prognosis and serves as an independent prognostic factor for ALM patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Insulin-like growth factor-II mRNA-binding protein 3 (IMP-3) is an RNA-binding protein implicated in various cancers.
  • IMP-3 expression has not been previously evaluated in acral lentiginous melanoma (ALM).

Purpose of the Study:

  • To investigate the expression of IMP-3 in ALM.
  • To determine the prognostic significance of IMP-3 in ALM patients.

Main Methods:

  • Immunohistochemistry was used to assess IMP-3 expression in 93 ALM tumor samples.
  • Univariate and multivariate survival analyses (Cox proportional hazard model) were performed.
  • Kaplan-Meier method was used for survival curve graphing.

Main Results:

  • IMP-3 was overexpressed in 75.3% of ALM tumors.
  • IMP-3 expression correlated with tumor thickness, stage, and predicted poorer survival outcomes (overall, melanoma-specific, recurrence-free, and distant metastasis-free).
  • IMP-3 was identified as an independent prognostic factor for melanoma-specific survival.

Conclusions:

  • Positive IMP-3 expression is a significant prognostic factor in ALM.
  • IMP-3 may serve as a valuable biomarker for predicting outcomes in ALM patients.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.8K
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.7K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K